Email updates

Keep up to date with the latest news and content from Respiratory Research and BioMed Central.

Open Access Research

Physiologic and molecular consequences of endothelial Bmpr2 mutation

Susan Majka12, Moira Hagen1, Thomas Blackwell4, Julie Harral1, Jennifer A Johnson4, Robert Gendron3, Helene Paradis3, Daniel Crona1, James E Loyd4, Eva Nozik-Grayck1, Kurt R Stenmark1 and James West4*

Author Affiliations

1 Cardiovascular Pulmonary Research, University of Colorado Health Sciences Center, Denver, Colorado, USA

2 Gates Center for Regenerative Medicine and Stem Cell Biology, University of Colorado Health Sciences Center, Denver, Colorado, USA

3 Division of Basic Medical Sciences, Memorial University of Newfoundland, Newfoundland, Canada

4 Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University, Nashville, Tennessee, USA

For all author emails, please log on.

Respiratory Research 2011, 12:84  doi:10.1186/1465-9921-12-84

Published: 22 June 2011

Abstract

Background

Pulmonary arterial hypertension (PAH) is thought to be driven by dysfunction of pulmonary vascular microendothelial cells (PMVEC). Most hereditary PAH is associated with BMPR2 mutations. However, the physiologic and molecular consequences of expression of BMPR2 mutations in PMVEC are unknown.

Methods

In vivo experiments were performed on adult mice with conditional endothelial-specific expression of the truncation mutation Bmpr2delx4+, with age-matched transactivator-only mice as controls. Phenotype was assessed by RVSP, counts of muscularized vessels and proliferating cells, and staining for thromboses, inflammatory cells, and apoptotic cells. The effects of BMPR2 knockdown in PMVEC by siRNA on rates of apoptosis were assessed. Affymetrix expression arrays were performed on PMVEC isolated and cultured from triple transgenic mice carrying the immortomouse gene, a transactivator, and either control, Bmpr2delx4+ or Bmpr2R899X mutation.

Results

Transgenic mice showed increased RVSP and corresponding muscularization of small vessels, with histologic alterations including thrombosis, increased inflammatory cells, increased proliferating cells, and a moderate increase in apoptotic cells. Expression arrays showed alterations in specific pathways consistent with the histologic changes. Bmpr2delx4+ and Bmpr2R899X mutations resulted in very similar alterations in proliferation, apoptosis, metabolism, and adhesion; Bmpr2delx4+ cells showed upregulation of platelet adhesion genes and cytokines not seen in Bmpr2R899X PMVEC. Bmpr2 mutation in PMVEC does not cause a loss of differentiation markers as was seen with Bmpr2 mutation in smooth muscle cells.

Conclusions

Bmpr2 mutation in PMVEC in vivo may drive PAH through multiple, potentially independent, downstream mechanisms, including proliferation, apoptosis, inflammation, and thrombosis.

Keywords:
Pulmonary Arterial Hypertension; mouse model; pulmonary vascular disease